Why Alzheimers-Drug Developer Cassava Sciences Stock Is Trending
Why Alzheimers-Drug Developer Cassava Sciences Stock Is Trending
Cassava Sciences, Inc. (NASDAQ:SAVA) shares are trading higher Wednesday after the company reported top-line results of a two-year clinical safety study of simufilam, an investigational oral drug for the proposed treatment of Alzheimer's disease dementia.
木薯科學公司（納斯達克股票代碼：SAVA）股價週三上漲，此前該公司公佈了對擬治療阿爾茨海默氏病癡呆的在研口服藥物simufilam的爲期兩年的臨床安全性研究的主要結果。
The Details:
細節：
The top-line results showed no decline in cognition scores in patients with mild Alzheimer's disease who received simufilam continuously for 24 months.
最重要的結果顯示，持續接受simufilam治療24個月的輕度阿爾茨海默氏病患者的認知分數沒有下降。
"We're fighting Alzheimer's disease by testing simufilam, a new type of drug that has a completely different mechanism of action from monoclonal antibody drug treatments," said Remi Barbier, CEO of Cassava.
木薯首席執行官雷米·巴比爾說：“我們正在通過測試simufilam來對抗阿爾茨海默氏病，這是一種與單克隆抗體藥物治療完全不同的新型藥物。”
"Stable ADAS-Cog scores over 2 years is clearly a desirable clinical outcome in Alzheimer's. Our data in mild patients may emphasize the importance of treating patients early in the disease."
“兩年內穩定的ADAS-Cog評分顯然是阿爾茨海默氏症理想的臨床結果。我們對輕度患者的數據可能凸顯了在疾病早期治療患者的重要性。”
Cassava Sciences shares have grabbed the attention of retail investors and short-sellers alike. The stock is one of the top trending tickers on Stocktwits, and a remarkable 33.49% of available shares are being sold short.
木薯科學的股票吸引了散戶投資者和賣空者的注意力。該股是Stocktwits上最熱門的股票之一，有33.49％的可用股票被賣空。
Related News: What's Going On With Bitcoin Miners Marathon Digital and Riot Platforms Stock?
相關新聞：比特幣礦工馬拉松數字和防暴平台股票怎麼了？
SAVA Price Action: According to Benzinga Pro, Cassava Sciences shares are up 2.2% at $24.18 at the time of publication.
SAVA價格走勢：根據Benzinga Pro的數據，木薯科學的股價在發佈時上漲2.2％，至24.18美元。
Image: Michal Jarmoluk from Pixabay
圖片：來自 Pixabay 的 Michal Jarmoluk
譯文內容由第三人軟體翻譯。